(Q44957615)

7 December 2017

Seven-day therapy for Helicobacter pylori in the United States (English)

1 reference

Helicobacter pylori infectious disease

7 December 2017

0 references

United States of America

0 references

1 reference

N Vakil

1

1 reference

7 December 2017

F Lanza

series ordinal

2

1 reference

7 December 2017

H Schwartz

series ordinal

3

1 reference

7 December 2017

J Barth

series ordinal

4

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Alimentary Pharmacology & Therapeutics

7 December 2017

1 reference

7 December 2017

20

1 reference

7 December 2017

99-107

1 reference

7 December 2017

1

1 reference

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

7 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Helicobacter pylori-related disease: guidelines for testing and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02029.X

10.1111/J.1365-2036.2004.02029.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference